Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Axsome Thera (NQ: AXSM ) 73.76 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 73.76 Bid (Size) 69.52 (10) Ask (Size) 80.00 (1) Prev. Close 73.76 Today's Range 73.76 - 73.76 52wk Range 55.02 - 98.40 Shares Outstanding 47,190,970 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Axsome Therapeutics Recognizes May as Mental Health Awareness Month Today 7:00 EDT From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire Performance YTD -4.28% -4.28% 1 Month -4.20% -4.20% 3 Month -19.75% -19.75% 6 Month +18.43% +18.43% 1 Year +4.22% +4.22% More News Read More 3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition April 30, 2024 Via InvestorPlace Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights April 29, 2024 Via Benzinga Analyst Ratings For Axsome Therapeutics April 10, 2024 Via Benzinga 2 Under-the-Radar Growth Stocks to Consider April 10, 2024 Via The Motley Fool What Analysts Are Saying About Axsome Therapeutics Stock March 19, 2024 Via Benzinga AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio? April 16, 2024 Via The Motley Fool Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting April 15, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 12, 2024 From Bragar Eagel & Squire Via GlobeNewswire What Analysts Are Saying About Axsome Therapeutics Stock February 27, 2024 Via Benzinga Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 April 10, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 03, 2024 From Bragar Eagel & Squire Via GlobeNewswire Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder April 01, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire 3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List March 27, 2024 Via InvestorPlace Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday March 26, 2024 Via Benzinga AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm March 25, 2024 From Bragar Eagel & Squire Via GlobeNewswire What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? March 25, 2024 Via Benzinga Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients March 25, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy March 25, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Buying These Dirt-Cheap Stocks Could Be a Brilliant Move March 23, 2024 Via The Motley Fool Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder March 19, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference March 05, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.